Fructosamine levels and hyperglycemia in preterm neonates

Judit Gyarmati, Margit Tokes-Fuzesi, G. Kovács, Valeria Gaal, Gabriella Vida, Tibor Ertl

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background: Hyperglycemia is a common complication of prematurity, which requires attention because of its high prevalence and multiple consequences. Serum fructosamine used in diabetic patients provides information about the average glucose concentration in the preceding period of 2-3 weeks. Objective: We investigated the physiologic characteristics of a glycemic marker, fructosamine, in preterm and term neonates. We also studied its association with hyperglycemia and related morbidities of preterm infants. Method: Fructosamine levels of 22 extremely premature (gestational age, GA: 25.8 ± 1.0 weeks), 36 moderately premature (GA: 29.8 ± 1.3 weeks) and 26 term infants (GA: 39.1 ± 1.3 weeks) were determined in the 1st week of life. Fructosamine assay was repeated in all preterm neonates in the 4th and 7th postnatal weeks. Hyperglycemic episodes and main morbidities of preterm infants were recorded and analyzed in association with fructosamine levels. Results: Preterm infants had higher fructosamine levels after birth compared to term infants and a postnatal fall was observed. Serum fructosamine did not show association with the occurrence of hyperglycemia or its main morbidities in preterm infants. Conclusion: In the framework of our study, we could not confirm the usefulness of fructosamine determination in the glycemic control of preterm neonates during the perinatal period.

Original languageEnglish
Pages (from-to)267-270
Number of pages4
JournalNeonatology
Volume95
Issue number4
DOIs
Publication statusPublished - Jun 2009

Fingerprint

Fructosamine
Hyperglycemia
Newborn Infant
Premature Infants
Morbidity
Serum
Gestational Age
Parturition
Glucose

Keywords

  • Fructosamine
  • Hyperglycemia
  • Prematurity

ASJC Scopus subject areas

  • Developmental Biology
  • Pediatrics, Perinatology, and Child Health

Cite this

Gyarmati, J., Tokes-Fuzesi, M., Kovács, G., Gaal, V., Vida, G., & Ertl, T. (2009). Fructosamine levels and hyperglycemia in preterm neonates. Neonatology, 95(4), 267-270. https://doi.org/10.1159/000166846

Fructosamine levels and hyperglycemia in preterm neonates. / Gyarmati, Judit; Tokes-Fuzesi, Margit; Kovács, G.; Gaal, Valeria; Vida, Gabriella; Ertl, Tibor.

In: Neonatology, Vol. 95, No. 4, 06.2009, p. 267-270.

Research output: Contribution to journalArticle

Gyarmati, J, Tokes-Fuzesi, M, Kovács, G, Gaal, V, Vida, G & Ertl, T 2009, 'Fructosamine levels and hyperglycemia in preterm neonates', Neonatology, vol. 95, no. 4, pp. 267-270. https://doi.org/10.1159/000166846
Gyarmati J, Tokes-Fuzesi M, Kovács G, Gaal V, Vida G, Ertl T. Fructosamine levels and hyperglycemia in preterm neonates. Neonatology. 2009 Jun;95(4):267-270. https://doi.org/10.1159/000166846
Gyarmati, Judit ; Tokes-Fuzesi, Margit ; Kovács, G. ; Gaal, Valeria ; Vida, Gabriella ; Ertl, Tibor. / Fructosamine levels and hyperglycemia in preterm neonates. In: Neonatology. 2009 ; Vol. 95, No. 4. pp. 267-270.
@article{cc28f516b2744b0ba939645956a6720c,
title = "Fructosamine levels and hyperglycemia in preterm neonates",
abstract = "Background: Hyperglycemia is a common complication of prematurity, which requires attention because of its high prevalence and multiple consequences. Serum fructosamine used in diabetic patients provides information about the average glucose concentration in the preceding period of 2-3 weeks. Objective: We investigated the physiologic characteristics of a glycemic marker, fructosamine, in preterm and term neonates. We also studied its association with hyperglycemia and related morbidities of preterm infants. Method: Fructosamine levels of 22 extremely premature (gestational age, GA: 25.8 ± 1.0 weeks), 36 moderately premature (GA: 29.8 ± 1.3 weeks) and 26 term infants (GA: 39.1 ± 1.3 weeks) were determined in the 1st week of life. Fructosamine assay was repeated in all preterm neonates in the 4th and 7th postnatal weeks. Hyperglycemic episodes and main morbidities of preterm infants were recorded and analyzed in association with fructosamine levels. Results: Preterm infants had higher fructosamine levels after birth compared to term infants and a postnatal fall was observed. Serum fructosamine did not show association with the occurrence of hyperglycemia or its main morbidities in preterm infants. Conclusion: In the framework of our study, we could not confirm the usefulness of fructosamine determination in the glycemic control of preterm neonates during the perinatal period.",
keywords = "Fructosamine, Hyperglycemia, Prematurity",
author = "Judit Gyarmati and Margit Tokes-Fuzesi and G. Kov{\'a}cs and Valeria Gaal and Gabriella Vida and Tibor Ertl",
year = "2009",
month = "6",
doi = "10.1159/000166846",
language = "English",
volume = "95",
pages = "267--270",
journal = "Neonatology",
issn = "1661-7800",
publisher = "S. Karger AG",
number = "4",

}

TY - JOUR

T1 - Fructosamine levels and hyperglycemia in preterm neonates

AU - Gyarmati, Judit

AU - Tokes-Fuzesi, Margit

AU - Kovács, G.

AU - Gaal, Valeria

AU - Vida, Gabriella

AU - Ertl, Tibor

PY - 2009/6

Y1 - 2009/6

N2 - Background: Hyperglycemia is a common complication of prematurity, which requires attention because of its high prevalence and multiple consequences. Serum fructosamine used in diabetic patients provides information about the average glucose concentration in the preceding period of 2-3 weeks. Objective: We investigated the physiologic characteristics of a glycemic marker, fructosamine, in preterm and term neonates. We also studied its association with hyperglycemia and related morbidities of preterm infants. Method: Fructosamine levels of 22 extremely premature (gestational age, GA: 25.8 ± 1.0 weeks), 36 moderately premature (GA: 29.8 ± 1.3 weeks) and 26 term infants (GA: 39.1 ± 1.3 weeks) were determined in the 1st week of life. Fructosamine assay was repeated in all preterm neonates in the 4th and 7th postnatal weeks. Hyperglycemic episodes and main morbidities of preterm infants were recorded and analyzed in association with fructosamine levels. Results: Preterm infants had higher fructosamine levels after birth compared to term infants and a postnatal fall was observed. Serum fructosamine did not show association with the occurrence of hyperglycemia or its main morbidities in preterm infants. Conclusion: In the framework of our study, we could not confirm the usefulness of fructosamine determination in the glycemic control of preterm neonates during the perinatal period.

AB - Background: Hyperglycemia is a common complication of prematurity, which requires attention because of its high prevalence and multiple consequences. Serum fructosamine used in diabetic patients provides information about the average glucose concentration in the preceding period of 2-3 weeks. Objective: We investigated the physiologic characteristics of a glycemic marker, fructosamine, in preterm and term neonates. We also studied its association with hyperglycemia and related morbidities of preterm infants. Method: Fructosamine levels of 22 extremely premature (gestational age, GA: 25.8 ± 1.0 weeks), 36 moderately premature (GA: 29.8 ± 1.3 weeks) and 26 term infants (GA: 39.1 ± 1.3 weeks) were determined in the 1st week of life. Fructosamine assay was repeated in all preterm neonates in the 4th and 7th postnatal weeks. Hyperglycemic episodes and main morbidities of preterm infants were recorded and analyzed in association with fructosamine levels. Results: Preterm infants had higher fructosamine levels after birth compared to term infants and a postnatal fall was observed. Serum fructosamine did not show association with the occurrence of hyperglycemia or its main morbidities in preterm infants. Conclusion: In the framework of our study, we could not confirm the usefulness of fructosamine determination in the glycemic control of preterm neonates during the perinatal period.

KW - Fructosamine

KW - Hyperglycemia

KW - Prematurity

UR - http://www.scopus.com/inward/record.url?scp=55149083082&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=55149083082&partnerID=8YFLogxK

U2 - 10.1159/000166846

DO - 10.1159/000166846

M3 - Article

C2 - 18984966

AN - SCOPUS:55149083082

VL - 95

SP - 267

EP - 270

JO - Neonatology

JF - Neonatology

SN - 1661-7800

IS - 4

ER -